skip to main content

S. 934 (115th): FDA Reauthorization Act of 2017

React to this bill with an emoji

Save your opinion on this bill on a six-point scale from strongly oppose to strongly support

Add Note All Positions »
(About Ads | Hide These Ads)

A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.

The bill’s titles are written by its sponsor.

The federal budget process occurs in two stages: appropriations, which set overall spending limits by agency or program, and authorizations, which direct how federal funds should (or should not) be used. Appropriation and authorization provisions are typically made for single fiscal years. A reauthorization bill like this one renews the authorizations of an expiring law.

Sponsor and status

Photo of sponsor Lamar Alexander

Lamar Alexander

Sponsor. Senior Senator for Tennessee. Republican.

Thumbnail of bill text
Read Text »
Last Updated: May 11, 2017
Length: 268 pages
Introduced:

Apr 25, 2017
115th Congress, 2017–2019

Status:
Ordered Reported

Provisions of this bill were incorporated into other bills which were enacted.

Provisions of this bill also appear in:

H.R. 2430: FDA Reauthorization Act of 2017
Enacted — Signed by the President on Aug 18, 2017. (compare text)

What stakeholders are saying

Institute for Spending Reform: SpendingTracker.org estimates S. 934 will add $10 billion in new spending through 2027.

History

Apr 25, 2017
 
Introduced

Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.

Read Text »

May 10, 2017
 
Considered by Senate Committee on Health, Education, Labor, and Pensions

A committee held a hearing or business meeting about the bill.

May 11, 2017
 
Ordered Reported

A committee has voted to issue a report to the full chamber recommending that the bill be considered further. Only about 1 in 4 bills are reported out of committee.

Read Updated Text » See Changes »

Jul 12, 2017
 
Related Bill — Passed House (Senate next)

This activity took place on a related bill, H.R. 2430 (115th), possibly in lieu of similar activity on S. 934 (115th).
Aug 3, 2017
 
Related Bill — Passed Senate

This activity took place on a related bill, H.R. 2430 (115th), possibly in lieu of similar activity on S. 934 (115th).
Aug 18, 2017
 
Related Bill — Enacted — Signed by the President

This activity took place on a related bill, H.R. 2430 (115th), possibly in lieu of similar activity on S. 934 (115th).

S. 934 (115th) was a bill in the United States Congress.

A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.

This bill was introduced in the 115th Congress, which met from Jan 3, 2017 to Jan 3, 2019. Legislation not enacted by the end of a Congress is cleared from the books.

How to cite this information.

We recommend the following MLA-formatted citation when using the information you see here in academic work:

“S. 934 — 115th Congress: FDA Reauthorization Act of 2017.” www.GovTrack.us. 2017. February 21, 2019 <https://www.govtrack.us/congress/bills/115/s934>

Where is this information from?

GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.